Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Sapphire Market 2010, Q4 Update - A report from Yole Développement

November 2, 2010 12:38 pm | by I-Micronews | News | Comments

Acute material shortage sent 2? wafer prices in the low $30?s. Shortage to be resolved by mid 2011

New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Nov. 2, 2010 /- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion...

TOPICS:

Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

COLORADO SPRINGS, Colo., Nov. 2, 2010 /- Cannabis Science, Inc. (OTC Bulletin Board: CBIS ), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce to its shareholders and the investment community that its Board of Directors have confirmed...

TOPICS:
Advertisement

Parkinson disease study now enrolling

November 2, 2010 12:36 pm | by Baylor College of Medicine | News | Comments

Enrollment has begun in a new double-blind Phase 2b study evaluating CERE-120 in Parkinson's disease patients. Baylor College of Medicine is one of eight clinical sites enrolling along with 11 major medical centers across the country. CERE-120 is a gene therapy product that delivers the...

TOPICS:

Deadline for Stand Up To Cancer's Innovative Research Grant Letters of Intent Fast Approaching

November 2, 2010 12:34 pm | by AACR | News | Comments

PHILADELPHIA - The American Association for Cancer Research reminds the cancer research community that the Letters of Intent deadline for Stand Up To Cancer's Innovative Research Grants (IRG) is less than two weeks away.

TOPICS:

Mednax 3Q profit rises 27 percent

November 2, 2010 11:45 am | by The Associated Press | News | Comments

National physician group Mednax Inc. said Tuesday that its third-quarter profit rose 27 percent as contributions from newly acquired practices helped boost revenue.Mednax earned $61.3 million, or $1.29 per share, up from $48.1 million, or $1.03 per share, in the same quarter last year. Revenue...

Emergency Medical Services 3Q profit rises

November 2, 2010 11:45 am | by The Associated Press | News | Comments

GREENWOOD VILLAGE, Colo. (AP) — Ambulance services provider Emergency Medical Services Corp. said Tuesday its third-quarter net income rose 27 percent on a boost in new contracts and acquisitions.EMS reported net income of $36.8 million, or 82 cents per share, up from $28.9 million, or 66 cents per...

Genstruct names systems biology vet Levine to board

November 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Genstruct Inc., a systems biology firm located in Cambridge, has appointed oncology and systems biology leader Arnold Levine to the company's board of directors.

Advertisement

Ironwood inches toward NDA on positive Phase 3 results

November 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

A treatment for irritable bowel syndrome developed by Cambridge-based Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc., of New York, has achieved positive results in a second Phase 3 clinical trial, meeting both primary and secondary endpoints.

Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant

November 2, 2010 10:36 am | by Bio-Medicine.Org | News | Comments

RYE, N.Y., Nov. 2, 2010 /- Curemark LLC , a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to...

TOPICS:

GREENGUARD's First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Architects and designers who visit the GREENGUARD Environmental Institute 's first-ever HEALTHCARE DESIGN.10 exhibit next week will have the opportunity to learn how low-emitting products and materials can help create healthier, more...

TOPICS:

GeNO LLC Submits Investigational New Drug Application for Its NITROsylâ„¢ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

COCOA, Fla., Nov. 2, 2010 /- GeNO LLC ( www.genollc.com ) a privately held, advanced development-stage technology company announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the GeNO NITROsyl (Inhaled Nitric...

TOPICS:

RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., Nov. 2, 2010 /- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has acquired a majority interest in Salter Labs ("Salter").  Founded in 1976 by Peter...

TOPICS:

Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Su...

November 2, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH)...

TOPICS:

Class I Medical Device Recall: Medtronic Octopus Nuvo Tissue Stabilizer, Model TSMICS1

November 2, 2010 10:30 am | by U.S. Food & Drug Administration | News | Comments

This device stabilizes and minimizes the motion of selected areas of the beating heart during minimally invasive cardiac procedures while directly visualizing the heart through a small cut in the chest cavity.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading